Literature DB >> 19248096

Specific association of type 1 diabetes mellitus with anti-cyclic citrullinated peptide-positive rheumatoid arthritis.

Katherine P Liao1, Marie Gunnarsson, Henrik Källberg, Bo Ding, Robert M Plenge, Leonid Padyukov, Elizabeth W Karlson, Lars Klareskog, Johan Askling, Lars Alfredsson.   

Abstract

OBJECTIVE: The co-occurrence of autoimmune diseases such as rheumatoid arthritis (RA) and type 1 diabetes mellitus (DM) has been reported in individuals and families. In this study, the strength and nature of this association were investigated at the population level in a Swedish case-control cohort.
METHODS: For this case-control study, 1,419 patients with incident RA diagnosed between 1996 and 2003 were recruited from university, public, and private rheumatology units throughout Sweden; 1,674 matched control subjects were recruited from the Swedish national population registry. Sera from the subjects were tested for the presence of antibodies to cyclic citrullinated peptide (anti-CCP), rheumatoid factor (RF), and the 620W PTPN22 allele. Information on a history of diabetes was obtained by questionnaire, telephone interview, and/or medical record review. The prevalence of type 1 DM and type 2 DM was compared between patients with incident RA and control subjects and further stratified for the presence of anti-CCP, RF, and the PTPN22 risk allele.
RESULTS: Type 1 DM was associated with an increased risk of RA (odds ratio [OR] 4.9, 95% confidence interval [95% CI] 1.8-13.1), and this association was specific for anti-CCP-positive RA (OR 7.3, 95% CI 2.7-20.0), but not anti-CCP-negative RA. Further adjustment for the presence of PTPN22 attenuated the risk of anti-CCP-positive RA in patients with type 1 DM to an OR of 5.3 (95% CI 1.5-18.7). No association between RA and type 2 DM was observed.
CONCLUSION: The association between type 1 DM and RA is specific for a particular RA subset, anti-CCP-positive RA. The risk of developing RA later in life in patients with type 1 DM may be attributed, in part, to the presence of the 620W PTPN22 allele, suggesting that this risk factor may represent a common pathway for the pathogenesis of these 2 diseases.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 19248096      PMCID: PMC2768389          DOI: 10.1002/art.24362

Source DB:  PubMed          Journal:  Arthritis Rheum        ISSN: 0004-3591


  39 in total

1.  Two independent alleles at 6q23 associated with risk of rheumatoid arthritis.

Authors:  Robert M Plenge; Chris Cotsapas; Leela Davies; Alkes L Price; Paul I W de Bakker; Julian Maller; Itsik Pe'er; Noel P Burtt; Brendan Blumenstiel; Matt DeFelice; Melissa Parkin; Rachel Barry; Wendy Winslow; Claire Healy; Robert R Graham; Benjamin M Neale; Elena Izmailova; Ronenn Roubenoff; Alexander N Parker; Roberta Glass; Elizabeth W Karlson; Nancy Maher; David A Hafler; David M Lee; Michael F Seldin; Elaine F Remmers; Annette T Lee; Leonid Padyukov; Lars Alfredsson; Jonathan Coblyn; Michael E Weinblatt; Stacey B Gabriel; Shaun Purcell; Lars Klareskog; Peter K Gregersen; Nancy A Shadick; Mark J Daly; David Altshuler
Journal:  Nat Genet       Date:  2007-11-04       Impact factor: 38.330

2.  Analysis of families in the multiple autoimmune disease genetics consortium (MADGC) collection: the PTPN22 620W allele associates with multiple autoimmune phenotypes.

Authors:  Lindsey A Criswell; Kirsten A Pfeiffer; Raymond F Lum; Bonnie Gonzales; Jill Novitzke; Marlena Kern; Kathy L Moser; Ann B Begovich; Victoria E H Carlton; Wentian Li; Annette T Lee; Ward Ortmann; Timothy W Behrens; Peter K Gregersen
Journal:  Am J Hum Genet       Date:  2005-02-17       Impact factor: 11.025

3.  Coexistence of four autoimmune diseases in one patient: the kaleidoscope of autoimmunity.

Authors:  Margarita Fallena Zonana; Edgardo Reyes; Arnoldo Kraus Weisman
Journal:  J Clin Rheumatol       Date:  2002-12       Impact factor: 3.517

4.  The HLA-DRB1 shared epitope alleles are primarily a risk factor for anti-cyclic citrullinated peptide antibodies and are not an independent risk factor for development of rheumatoid arthritis.

Authors:  Annette H M van der Helm-van Mil; Kirsten N Verpoort; Ferdinand C Breedveld; Tom W J Huizinga; René E M Toes; René R P de Vries
Journal:  Arthritis Rheum       Date:  2006-04

5.  Incidence, prevalence, and mortality of diabetes in a large population. A report from the Skaraborg Diabetes Registry.

Authors:  B Berger; G Stenström; G Sundkvist
Journal:  Diabetes Care       Date:  1999-05       Impact factor: 19.112

6.  Replication of putative candidate-gene associations with rheumatoid arthritis in >4,000 samples from North America and Sweden: association of susceptibility with PTPN22, CTLA4, and PADI4.

Authors:  Robert M Plenge; Leonid Padyukov; Elaine F Remmers; Shaun Purcell; Annette T Lee; Elizabeth W Karlson; Frederick Wolfe; Daniel L Kastner; Lars Alfredsson; David Altshuler; Peter K Gregersen; Lars Klareskog; John D Rioux
Journal:  Am J Hum Genet       Date:  2005-11-01       Impact factor: 11.025

7.  Silica exposure is associated with increased risk of developing rheumatoid arthritis: results from the Swedish EIRA study.

Authors:  P Stolt; H Källberg; I Lundberg; B Sjögren; L Klareskog; L Alfredsson
Journal:  Ann Rheum Dis       Date:  2004-08-19       Impact factor: 19.103

8.  A gene-environment interaction between smoking and shared epitope genes in HLA-DR provides a high risk of seropositive rheumatoid arthritis.

Authors:  Leonid Padyukov; Camilla Silva; Patrik Stolt; Lars Alfredsson; Lars Klareskog
Journal:  Arthritis Rheum       Date:  2004-10

9.  A missense single-nucleotide polymorphism in a gene encoding a protein tyrosine phosphatase (PTPN22) is associated with rheumatoid arthritis.

Authors:  Ann B Begovich; Victoria E H Carlton; Lee A Honigberg; Steven J Schrodi; Anand P Chokkalingam; Heather C Alexander; Kristin G Ardlie; Qiqing Huang; Ashley M Smith; Jill M Spoerke; Marion T Conn; Monica Chang; Sheng-Yung P Chang; Randall K Saiki; Joseph J Catanese; Diane U Leong; Veronica E Garcia; Linda B McAllister; Douglas A Jeffery; Annette T Lee; Franak Batliwalla; Elaine Remmers; Lindsey A Criswell; Michael F Seldin; Daniel L Kastner; Christopher I Amos; John J Sninsky; Peter K Gregersen
Journal:  Am J Hum Genet       Date:  2004-06-18       Impact factor: 11.025

Review 10.  Genetic susceptibility factors in type 1 diabetes: linkage, disequilibrium and functional analyses.

Authors:  J X She; M P Marron
Journal:  Curr Opin Immunol       Date:  1998-12       Impact factor: 7.486

View more
  26 in total

1.  Management of cardiovascular risk in patients with rheumatoid arthritis: evidence and expert opinion.

Authors:  Inge A M van den Oever; Alper M van Sijl; Michael T Nurmohamed
Journal:  Ther Adv Musculoskelet Dis       Date:  2013-08       Impact factor: 5.346

2.  High prevalence of systemic rheumatic diseases in women with type 1 diabetes.

Authors:  Yicheng K Bao; Maamoun Salam; Deborah Parks; Janet B McGill; Jing Hughes
Journal:  J Diabetes Complications       Date:  2018-06-07       Impact factor: 2.852

3.  Genetic link of type 1 diabetes susceptibility loci with rheumatoid arthritis in Pakistani patients.

Authors:  Aysha Karim Kiani; Sidrah Jahangir; Sidrah Jahngir; Peter John; Attya Bhatti; Asima Zia; Xingbin Wang; F Yesim Demirci; M Ilyas Kamboh
Journal:  Immunogenetics       Date:  2015-04-24       Impact factor: 2.846

Review 4.  Traditional cardiovascular risk factors, inflammation and cardiovascular risk in rheumatoid arthritis.

Authors:  Katherine P Liao; Daniel H Solomon
Journal:  Rheumatology (Oxford)       Date:  2012-09-16       Impact factor: 7.580

5.  Dominant-negative loss of function arises from a second, more frequent variant within the SAND domain of autoimmune regulator (AIRE).

Authors:  Jordan K Abbott; Yu-San Huoh; Paul R Reynolds; Liping Yu; Marian Rewers; Monica Reddy; Mark S Anderson; Sun Hur; Erwin W Gelfand
Journal:  J Autoimmun       Date:  2017-11-10       Impact factor: 7.094

Review 6.  Type 1 diabetes and polyglandular autoimmune syndrome: A review.

Authors:  Martin P Hansen; Nina Matheis; George J Kahaly
Journal:  World J Diabetes       Date:  2015-02-15

7.  HLA-dependent autoantibodies against post-translationally modified collagen type II in type 1 diabetes mellitus.

Authors:  R Strollo; P Rizzo; M Spoletini; R Landy; C Hughes; F Ponchel; N Napoli; A Palermo; R Buzzetti; P Pozzilli; A Nissim
Journal:  Diabetologia       Date:  2012-11-19       Impact factor: 10.122

Review 8.  Immune-Modulating Therapy for Rheumatologic Disease: Implications for Patients with Diabetes.

Authors:  Scott J Pilla; Amy Q Quan; Emily L Germain-Lee; David B Hellmann; Nestoras N Mathioudakis
Journal:  Curr Diab Rep       Date:  2016-10       Impact factor: 4.810

Review 9.  Tyrosine phosphatase PTPN22: multifunctional regulator of immune signaling, development, and disease.

Authors:  Nunzio Bottini; Erik J Peterson
Journal:  Annu Rev Immunol       Date:  2013-12-18       Impact factor: 28.527

10.  Comorbidities As Risk Factors for Rheumatoid Arthritis and Their Accrual After Diagnosis.

Authors:  Vanessa L Kronzer; Cynthia S Crowson; Jeffrey A Sparks; Elena Myasoedova; John M Davis
Journal:  Mayo Clin Proc       Date:  2019-11-20       Impact factor: 7.616

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.